Cardiac valve disease and low-dose dopamine agonist therapy: An artefact of reporting bias?

Clinical Endocrinology

Volumn 74, Issue 5, 2011, Pages 608-610

  Gu, Haotian ^a,b   Luck, Sara ^a   Carroll, Paul V ^a   Powrie, Jake ^a   Chambers, John ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART VALVE REGURGITATION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MALE; MITRAL VALVE REGURGITATION; OBSERVER BIAS; PRIORITY JOURNAL; PROLACTINOMA; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; VALVULAR HEART DISEASE;

ADULT; ANTINEOPLASTIC AGENTS; ARTIFACTS; BIAS (EPIDEMIOLOGY); DOPAMINE AGONISTS; ECHOCARDIOGRAPHY; ERGOLINES; FEMALE; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; PITUITARY NEOPLASMS; PROLACTINOMA; TRICUSPID VALVE INSUFFICIENCY;

EID: 79953764897     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03973.x     Document Type: Article

References (13)

1. Nutt, J.G., &, Wooten, G.F., (2005) Diagnosis and initial management of Parkinson's diease. New England Journal of Medicine, 353, 1021-1027. (Pubitemid 41262336)
2. Zanettini, R., Antonini, A., Gatto, G., et al. (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine, 356, 39-46. (Pubitemid 46041752)
3. Schade, R., Andersohn, F., Suissa, S., et al. (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine, 356, 29-38. (Pubitemid 46041751)
4. European Medicines Agency. (2008) EMEA Recommends New Warnings and Contraindications for Ergot-Derived Dopamine Agonists. London.
5. Colao, A., Galderisi, M., Sarno, A.D., et al. (2007) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. Journal of Clinical Endocrinology and Metabolism, 93, 3777-3784.
6. Kars, M., Delgado, V., Holman, E.R., et al. (2008) Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. Journal of Clinical Endocrinology and Metabolism, 93, 3348-3356.
7. Bogazzi, F., Buralli, S., Manetti, L., et al. (2008) Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. International Journal of Clinical Practice, 62, 1864-1869.
8. Lancellotti, P., Livadariu, E., Markov, M., et al. (2008) Cabergoline and the risk of valvular lesions in endocrine disease. European Journal of Endocrinology, 159, 1-5. (Pubitemid 351969123)
9. Vallette, S., Serri, K., Rivera, J., et al. (2009) Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary, 12, 153-157.
10. Wakil, A., Rigby, A.S., Clark, A.L., et al. (2008) Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European Journal of Endocrinology, 159, R11-R14.
11. Popescu, B.A., Andrade, M.J., Badano, L.P., et al. (2009) European association of echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies. European Journal of Echocardiography, 9, 438-448.
12. Zoghbi, W.A., Enriquez-Sarano, M., Foster, E., et al. (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. Journal of American Society of Echocardiography, 16, 777-802. (Pubitemid 37391035)
13. Tan, T., Carbrita, I.Z., Hensman, D., et al. (2010) Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clinical Endocrinology, 73, 369-374.